AU2002322056A1 - Method of mycophenolate mofetil preparation - Google Patents

Method of mycophenolate mofetil preparation

Info

Publication number
AU2002322056A1
AU2002322056A1 AU2002322056A AU2002322056A AU2002322056A1 AU 2002322056 A1 AU2002322056 A1 AU 2002322056A1 AU 2002322056 A AU2002322056 A AU 2002322056A AU 2002322056 A AU2002322056 A AU 2002322056A AU 2002322056 A1 AU2002322056 A1 AU 2002322056A1
Authority
AU
Australia
Prior art keywords
mycophenolate mofetil
process according
mycophenolic acid
solvent
morpholιnoethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002322056A
Inventor
Miloslav Chudlik
Ales Husek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ivax Pharmaceuticals sro
Original Assignee
Ivax Pharmaceuticals sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Pharmaceuticals sro filed Critical Ivax Pharmaceuticals sro
Publication of AU2002322056A1 publication Critical patent/AU2002322056A1/en
Assigned to IVAX PHARMACEUTICALS S.R.O. reassignment IVAX PHARMACEUTICALS S.R.O. Request for Assignment Assignors: IVAX C.R., A.S.
Abandoned legal-status Critical Current

Links

Description

Method of Mycophenolate Mofetil Preparation
Field of the invention
This invention refers to method of mycophenolate mofetil preparation according to the formula I
where
R1 is 2-(4-morpholinyl)ethyl, R2 is hydrogen atom.
Mycophenolate mofetil (I) is used as an immunosuppressive for prophylactic treatment in combination with other immunosuppressives (cyclospoπ'ne A, prednisone), or for treatment of refractory rejections in patients after renal transplantation. Chemically, mycophenolate mofetil is 2-(4-morpholinyl)ethyl ester of mycophenolic acid (R1 = R2 = H), which has cytostatic effect. It carries out inosine monophosphate dehydrogenaze selective inhibition, and this way also de πovo synthesis pathway of guanosine nucleotides and their incorporation into DNK. This way cytostatic effect to lymphocytes is higher that to other cells.
Background Art
Synthesis of mycophenolate mofetil in accordance with the formula I (R1 = 2- morpholinoethyl, R2 = H) is described in the basic patent EP 281 713 B1 (1987) and several other patents: US No. 4 808 592 (1989), US No. 4 753 935 (1988), US No. 4 952 579 (1990), US No. 4 984 793 (1990), US No. 4 786 637 (1988). In accordance with these patents mycophenolate mofetil may be prepared using two standard esterification methods (see Synthetic Organic Chemistry, R.B. Wagner and H.D. Zook (Wiley, New York), 1956, pages 479 to 532): reaction of mycophenolic chloride with excessive amount of 2- morpholinoethanol and condensation using dicyclohexylcarbodiimide (DDC). Esterification via the acid chloride is based on reaction of excessive amount of 2-morpholiπoethaπol with mycophenolic acid chloride that has been prepared from mycophenolic acid using suitable chlorinating agent (thionylchloride, oxalylchloride etc.). Use of the excessive amount of 2- morpholinoethanol (up to 3 equivalents), formation of dimmers (about 2%, R1 = H or 2- morpholiπoethyl, R2 = mycophenolic acid) represents a disadvantage of the two-stage process, there are also problems with colour of the product Formation of unjustifiable amount of impurities and dicyclohexylurea that may be eliminated from the reaction mixture only by a chromatography is a disadvantage of DCC use as an activating agent
The US patent No 5 247 083 dated 1993 describes preparation of mycophenolate mofetil by reflux of mycophenolic acid and 2-morpholιnoethanol in a suitable solvent or a mixture of solvents under azeotropic water separation Dichloromethane, benzene, toluene, xylene and higher hydrocarbons are given in the claims and examples The most suitable solvents are toluene, xylene and their mixture in proportion 1 1 A long reaction period necessary to reach sufficient conversion (depending on the solvent used about 60 to 100 hours) and colour of the product (light violet crystal) are the disadvantages of this method
Object of the international application No WO 00/34503 dated 2000 is mycophenolic acid esterification with 2-morpholιnoethanol using enzyme catalysis This way mycophenolate mofetil may be obtained in high yield and purity, however, the method may not be used in industry Within this patent method of mycophenolic acid esterification by boiling in 2-morpholιnoethanol without any solvent is described but considering price of 2- morpholinoethanol the method is not suitable either
Disclosure of the Invention it was surprising during optimisation of mycophenolate mofetil preparation by mycophenolic acid direct esterification with 2-morpholιnoethanol under azeotropic separation of water that thanks to use of dibutyl ether, unlike toluene or xylene, the reaction is slightly accelerated Thanks to the use of higher ethers the problems with the colour of the product that had been monitored in toluene or xylene were eliminated Low solubility of mycophenolate mofetil in higher ethers is also a favourable property as it makes product isolation from high-boiling solvent easier That is why the proposed method represents the most favourable alternative to the method described under the patent US No 5 247 083
Process in accordance with invention solves preparation of mycophenolate mofetil as follows
Mycophenolic acid is esteπfied by reflux in ethers (general formula R3OR4, where R3, R4 = alkyl, aryl), boiling point of which is 120°C as minimum, under azeotropic separation of water and under use of excessive amount of 2-morpholιnoethanol (1 01 to 3 molar equivalents) Reaction time is in the range 5 to 50 hours and reaction temperature is higher than 120°C depending on the solvent used The ratio mycophenolic acid solvent used is in the range 1 g 2 ml to 1 g 5 ml Conversion is in the range 80 to 98% After raw product recrystallization mycophenolate mofetil is obtained with purity 99 0% as minimum and yield 70% as minimum
Examples
The invention is illustrated with the following examples that however do not limit extent of the patent in any way
E x a m p l e 1
Mycophenolate mofetil, use of dibutyl ether as solvent
10 g mycophenolic acid were put in a reaction flask with a reflux cooler together with 20 ml dibutyl ether Stirring vigorously the mixture was warmed up to the temperature of 50 to 60°C and then 4 ml 2-morpholιnoethanol were dropped in The reaction mixture was warmed up to boiling under azeotropic separation of water After 48 hours the mixture was cooled up to the laboratory temperature and diluted with 20 ml dichloromethane The solution was extracted twice with 10 ml 0 5 M aqueous K2C03 and once with 10 ml of water Then dichloromethane was distilled off under vacuum and the suspension was cooled up to 10 to 15°C Crystallized mycophenolate mofetil was removed by suction and recrystallized from ethyl acetate After the removal by suction and drying the crystals 1 1 g (78%) mycophenolate mofetil was obtained with purity > 99 0% (HPLC)
E x a m p l e 2
Mycophenolate mofetil, use of dipentyl ether as solvent
10 g mycophenolic acid were put in a reaction flask with a reflux cooler together with 20 ml dipentyl ether Stirring vigorously the mixture was warmed up to the temperature of 50 to 60°C and then 4 ml 2-morpholιnoethanol were dropped in The reaction mixture was warmed up to boiling under azeotropic separation of water After 6 hours the mixture was cooled up to the laboratory temperature and diluted with 20 ml dichloromethane The solution was extracted twice with 10 ml 0 5 M aqueous K2C03 and once with 10 ml of water Then dichloromethane was distilled off under vacuum and the suspension was cooled up to 10 to 15°C Crystallized mycophenolate mofetil was removed by suction and recrystallized from ethyl acetate After the removal by suction and drying the crystals 10 g (71 %) mycophenolate mofetil was obtained with purity > 99 0% (HPLC) E x a m p l e 3
Mycophenolate mofetil; use excess of 2-morfpholinoethanol
10 g mycophenolic acid was put in a reaction flask with a reflux cooler together with 20 ml dibutyl ether. Stirring vigorously the mixture was warmed up to the temperature of 50 to 60°C and then 4,8 ml 2-morpholinoethanol was added in. The reaction mixture was warmed up to boiling under azeotropic separation of water. After 15 hours the mixture was cooled up to the laboratory temperature and diluted with 25 ml dichloromethane. The solution was extracted twice with 10 ml of 1 % aqueous ammonia and once with 10 ml of water. Then dichloromethane was distilled off under vacuum and the suspension was cooled up to 10 to 15°C. Crystallized mycophenolate mofetil was removed by suction and recrystallized from ethyl acetate. After the removal by suction and drying the crystals 11 ,1 g (82 %) mycophenolate mofetil was obtained with purity > 99.0% (HPLC).

Claims (1)

  1. C L A I M S
    The process of preparation of mycophenolate mofetil by direct esterification of mycophenolic acid and 2-morpholιnoethanol characterized with esterification carried out under boiling in ethers
    The process according to claim 1, characterized with the use of ethers as solvent of the general formula R30R4, where R3 and R4 are independently alkyl or aryl
    The process according to claim 2, characterized with the use of ethers as solvent of boiling point above 120 °C
    The process according to claim 1 , characterized with the use of 1 01 up to 3 0 molar equivalents of 2-morpholιnoethanol
    The process according to claim 3, characterized with the use of dibutylether as an inert solvent
    The process according to claim 5, characterized with the starting temperature of the reaction ranging between 130 °C and 138 °C and the final temperature of the reaction ranging between 140 °C and 145 °C
    The process according to claim 5, characterized with the reflux time ranging from 30 to 80 hours
    The process according to claim 5, characterized with the ratio of mycophenolic acid to dibutylether ranging from 1g/2ml to 1g/5ml
AU2002322056A 2001-06-08 2002-06-08 Method of mycophenolate mofetil preparation Abandoned AU2002322056A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZPV2001-2071 2001-06-08

Publications (1)

Publication Number Publication Date
AU2002322056A1 true AU2002322056A1 (en) 2002-12-23

Family

ID=

Similar Documents

Publication Publication Date Title
EP1421081A1 (en) Method of mycophenolate mofetil preparation
CA2291068C (en) Method for the preparation of citalopram
US6392060B2 (en) Method for the preparation of 5-cyanophthalide
HU213186B (en) Process for the preparation of fenoxy-pyrimidine derivatives
BG64823B1 (en) Method for the preparation of citalopram
WO1999059999A1 (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2 INHIBITORY EFFECT
JP4667691B2 (en) Process for the preparation of nitroxyalkyl esters of naproxen
US7227021B2 (en) Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
US20020177722A1 (en) Method for the preparation of citalopram
AU2002322056A1 (en) Method of mycophenolate mofetil preparation
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
US20080300404A1 (en) Process for the Preparation of Mycophenolate Mofetil
JP2002536426A (en) Process for producing symmetric and asymmetric carbonates
JP3184345B2 (en) Method for producing 5-chlorooxindole
JP2603108B2 (en) Anilinopyrimidine derivative
JPH05279345A (en) Production of 4,6-dialkoxypyrimidine
CA2058144C (en) Process for the production of threo-4-alkoxy-5-(arylhydroxymethyl)-2(5h)-furanones
US6355836B1 (en) Process for the preparation of cis 5-fluoro-2-methyl-1[p-(methylthio)benzyliden]-inden-3-acetic acid
JP2002535389A (en) Synthesis of ethyleneimine dimer
RU2061676C1 (en) Process for preparing 2,6-dichlorodiphenylamine
JPH0713061B2 (en) 3-aryloxy-5-aminopyrazole compounds
JPH11209345A (en) Production of intermediate for drug
JPH0667941B2 (en) 6-Aryloxy-1H-pyrazolo [1,5-b] -1,2,4-triazole compound
JP2001261630A (en) Method for producing cyanoacylurea compounds
BE862384A (en) PYRIMIDOQUINOXALINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND A CONTAINER FOR THE TREATMENT OF ASTHMA